{"schema_version":"secwatch.filing_event.v1","accession":"0001759425-25-000057","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2025-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.355212+00:00","generated_at":"2026-05-16T19:21:10.445369+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mirum receives Sandoz Paragraph IV notice challenging Livmarli patents; plans to sue","bullets":["Sandoz filed ANDA seeking FDA approval for generic Livmarli (maralixibat).","Sandoz alleges five Livmarli Orange Book patents are invalid or not infringed.","Mirum has 45 days to sue, triggering a 30-month FDA approval stay.","Mirum expects additional Paragraph IV notices from other ANDA filers.","Company vows to vigorously enforce IP and seek a permanent injunction."],"urls":{"canonical":"https://secwatch.observer/filing/0001759425-25-000057","json":"https://secwatch.observer/filing/0001759425-25-000057.json","markdown":"https://secwatch.observer/filing/0001759425-25-000057.md","text":"https://secwatch.observer/filing/0001759425-25-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000175942525000057/0001759425-25-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000175942525000057/mirm-20251117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:21:10.445369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}